Status:
NOT_YET_RECRUITING
Detection of Bleeding Disorders Diagnosed After Vaginal Delivery Complicated by Severe Postpartum Hemorrhage
Lead Sponsor:
University Hospital, Brest
Conditions:
Severe Postpartum Hemorrhage
Eligibility:
FEMALE
18+ years
Brief Summary
A cohort study designed to detect bleeding disorders diagnosed in women who experienced severe postpartum hemorrhage after vaginal delivery
Detailed Description
Severe postpartum hemorrhage (PPH), defined as blood loss ≥ 1000 mL within 24 hours after delivery, is a common complication of childbirth (2% of deliveries in France and Europe). It is associated wit...
Eligibility Criteria
Inclusion
- Women ≥ 18 years old
- Who experienced severe postpartum hemorrhage, defined as blood loss ≥ 1000 mL, following a vaginal delivery in the previous 12 months, in a maternity unit in Finistère
Exclusion
- Women who are pregnant at the time of inclusion
- Women with a known hereditary bleeding disorder (Willebrand's disease, hemophilia carrier, etc.) or acute or chronic Immune thrombocytopenia (ITP) prior to delivery.
- Women with a known other bleeding pathology prior to delivery
- Women taking a treatment that interferes with hemostasis, such as aspirin, anticoagulants or non-steroidal anti-inflammatory drugs (biological sampling may be postponed until after the interfering treatment has stopped, in the case of occasional use of the latter).
- Women on long-term anticoagulant or antiaggregant therapy
- Women under legal protection,
- Women not affiliated to the French social security system.
Key Trial Info
Start Date :
November 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 15 2029
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06970860
Start Date
November 15 2025
End Date
September 15 2029
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Brest
Brest, France, 29200